As we age, chronic inflammation becomes more prevalent in our cells, leading to various diseases like psoriasis, rheumatoid arthritis, and cancer. Addressing this issue, Longaevus conducted extensive research, screening over 700 genes in search of genetic solutions. Our ground-breaking findings have revealed that reducing the activity of LONG-001 and LONG-002 have a remarkable rejuvenating effect on human cells by suppressing the inflammation cascade.

With this promising discovery, Longaevus is committed to presenting potential leads for this target in the upcoming year. Our goal is to develop innovative therapies that cater to unmet clinical needs, particularly in treating conditions like psoriasis and rheumatoid arthritis. By harnessing the power of LONG-001 and LONG-002, we aspire to bring new hope to individuals suffering from these debilitating diseases and significantly improve their quality of life.

The intricate mechanism of chronic inflammation in aging cells involves a multifaceted interplay of factors, including DNA damage, accumulation of senescent cells, and compromised immune function. These alterations create an immune system imbalance and trigger the release of pro-inflammatory molecules, leading to tissue damage and disease. To combat this complex issue, researchers are exploring various strategies like anti-inflammatory drugs and other interventions. However, existing solutions often focus on the final stages of the inflammatory cascade and may not effectively prevent all pathogenic processes involved in chronic inflammation.

At Longaevus, we take a different approach in addressing chronic inflammation associated with aging. Instead of targeting individual pathways, we identify and screen for specific genes that become overactivated during the pathological inflammatory process. By homing in on these activated genes, we tackle the entire pathologic inflammatory cascade simultaneously. This comprehensive method allows us to provide a more effective solution, targeting multiple pathways in unison, to counteract chronic inflammation associated with aging. Through our innovative approach, we aim to bring forth ground-breaking solutions that hold the potential to significantly improve the lives of individuals suffering from age-related inflammatory diseases.

In our research, we utilized a combination of primary skin fibroblasts obtained from various elderly patients. Our investigation extended beyond solely examining inflammation; we also measured multiple markers to assess various changes and cell viability readouts. To inhibit the target genes, we employed lentiviral shRNA, which allowed us to observe the effects more effectively.

As a result of these experiments, our company successfully identified a remarkable rejuvenating effect on human cells when we reduced the activity of two crucial genes, namely LONG-001 and LONG-002. These genes play a pivotal role in suppressing inflammation caused by the accumulation of DNA damage associated with aging. Moreover, our findings indicate that targeting LONG-001 and LONG-002 has the potential to reverse multiple aging phenotypes, offering exciting possibilities for age-related conditions.

We are dedicated to leveraging the knowledge gained from these discoveries to provide effective solutions for chronic inflammation and to enhance the overall quality of life for individuals affected by age-related diseases. By focusing on these specific genes, we aim to pave the way for innovative therapies that have the potential to bring transformative benefits to patients suffering from age-related ailments.